Mason Marks

Dr. Mason Marks advises clients on state and federal controlled substance regulation and licensing. He is a law professor at the University of New Hampshire Franklin Pierce School of Law, a Senior Fellow at the Petrie-Flom Center at Harvard Law School, and an affiliated fellow at the Information Society Project at Yale Law School.

A resident of Portland, Oregon, Mason divides his time between New England and the Pacific Northwest. He enjoys travel, hiking, and exploring the Oregon wilderness.

psilocybin controlled substances act reschedule

A Strategy for Rescheduling Psilocybin

Public and scientific interest in psychedelics such as psilocybin and MDMA is expanding. Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Psilocybin, a

kratom fda ban

The FDA’s Proposed Kratom Ban is a Mistake

Trust in the U.S. Food and Drug Administration (FDA) declined after its approval of the controversial Alzheimer’s drug aducanumab. Three experts resigned amid allegations that the FDA had caved to industry pressure. Some argue that its credibility has reached a new low. These events should have prompted the FDA to pause, reflect, and work to repair its reputation. Instead, the

oregon psilocybin licensing board

Oregon Psilocybin: Advisory Board and Licensing Update

On March 18, Governor Kate Brown appointed members to the Oregon Psilocybin Advisory Board, which held its first meeting on March 31. Since then, the Board has met monthly and created five subcommittees to study facets of the emerging psilocybin industry including research, equity, manufacturing, training, and licensing. I chair the Licensing Subcommittee, which focuses